Source comparison
CJC-1295 No DAC Compare to Other Research Peptides: Head-to-Head Comparison
Modified GRF(1-29) (CJC No DAC) GHRH receptor agonist ~30 min 2–3× daily 15–20 min Minimal High (with GHRPs) Ideal for pulsatile protocols mimicking physiologic GH secretion. Requires frequent dosing but preserves endogenous rhythm CJC-1295 with DAC GHRH recep
This comparison does not assign a generated winner or score.
- Modified GRF(1-29) (CJC No DAC)
- GHRH receptor agonist
- ~30 min
- 2–3× daily
- 15–20 min
- Minimal
- High (with GHRPs)
- Ideal for pulsatile protocols mimicking physiologic GH secretion. Requires frequent dosing but preserves endogenous rhythm
- CJC-1295 with DAC
- GHRH receptor agonist (albumin-bound)
- 6–8 days
- 2× weekly
- 2–4 hours
- Moderate
- Best for sustained GH elevation studies. Loses pulsatility, simplifies dosing, may suppress endogenous secretion over time
- GHRP-2
- Ghrelin receptor agonist
- 20–30 min
- Moderate (cortisol, prolactin at >100mcg)
- High (with GHRH peptides)
- Potent GH amplifier in synergy. Cortisol elevation limits chronic high-dose use, cost-effective for multi-dose protocols
- GHRP-6
- Moderate (appetite stimulation significant)
- Similar to GHRP-2 but with pronounced ghrelin-mediated appetite increase. Useful for metabolic studies, confounding for pure GH research
- Ipamorelin
- Selective ghrelin receptor agonist
- ~2 hours
- 30–45 min
- Cleanest GHRP for synergy. Negligible cortisol/prolactin elevation, longer half-life allows slightly less frequent dosing, higher cost
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- ~24 hours
- 1× daily
- 2–3 hours (sustained)
- Moderate (appetite, mild insulin resistance)
- None (monotherapy only)
- Eliminates injection requirement, produces flat sustained GH elevation. No pulsatility, potential receptor desensitisation after 6–8 weeks
- The comparison reveals a pattern: short-acting peptides (modified GRF, GHRPs) require frequent administration but preserve physiologic variability. Long-acting peptides (CJC-DAC, MK-677) simplify protocols but flatten GH secretion patterns. Research questions requiring acute response measurement, circadian rhythm preservation, or receptor sensitivity studies default to short-acting compounds. Chronic exposure studies, IGF-1 elevation research, or simplified dosing protocols favour long-acting alternatives.